AstraZeneca reports robust efficacy and long-term prevention in new drug trials

Sunday, Nov 21, 2021

AstraZeneca has recently announced that data from the AZD7442 COVID-19 PROVENT and TACKLE outpatient treatment phase III trials both showed robust efficacy from a one-time intramuscular dose of the long-acting antibody combination.